| Identification | Back Directory | [Name]
COMBRETASTATIN A1 | [CAS]
109971-63-3 | [Synonyms]
COMBRETASTATIN A1
(Z)-3',4,4',5'-Tetramethoxystilbene-2,3-diol
(Z)-3,4,4',5-Tetramethoxy-2',3'-dihydroxystilbene
3-Methoxy-6-[(Z)-3,4,5-trimethoxystyryl]-1,2-benzenediol
(Z)-3-Methoxy-6-(3,4,5-Trimethoxystyryl)Benzene-1,2-Diol
3-methoxy-6-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]benzene-1,2-diol
1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-
Combretastatin A1( 3-Methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzene-1,2-diol ) | [Molecular Formula]
C18H20O6 | [MDL Number]
MFCD00877177 | [MOL File]
109971-63-3.mol | [Molecular Weight]
332.35 |
| Chemical Properties | Back Directory | [Melting point ]
113-115 °C(Solv: chloroform (67-66-3); hexane (110-54-3)) | [Boiling point ]
528.4±50.0 °C(Predicted) | [density ]
1.251±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 5 mg/ml; DMSO: 5 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 3 mg/ml | [form ]
A crystalline solid | [pka]
8.89±0.45(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects[1][2][3]. | [in vivo]
Combretastatin A-1 (1-4 mg/kg; i.v. every other day for 4 weeks) significantly reduces the tumor volume in HepG2 subcutaneous xenograft model[2].
Combretastatin A-1 (2 mg/kg; every other day for 21 days) shows enhanced apoptosis in orthotopic hepatocellular carcinoma mouse model[2]. | Animal Model: | Male athymic BALB/c nu/nu mice (16-18 g; 4-6 weeks old) were inoculated with HepG2 cells[2] | | Dosage: | 1, 2, 4?mg/kg | | Administration: | I.v. every other day for 4 weeks | | Result: | Resulted in a significant tumor volume reduction at the dose of 2?mg/kg or 4?mg/kg. |
| [storage]
Store at -20°C | [References]
[1] Pettit GR, et, al. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod. Jan-Feb 1987;50(1):119-31. DOI:10.1021/np50049a016
[2] Mao J, et, al. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Cancer Lett. 2016 Sep 28;380(1):134-43. DOI:10.1016/j.canlet.2016.06.020
[3] Holwell SE, et, al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res. Nov-Dec 2002;22(6C):3933-40. PMID:12553015 |
|
|